The Bugle App
The Bugle App
Your local news hub
Latest issueFeaturesSportsFolk By The Sea24 Hour Defibrillator sitesSocial Media
The Bugle App

Expanded access to treatment for UTIs in the Illawarra and South Coast

The Bugle App

Brooke Pittman

28 May 2024, 2:00 AM

Expanded access to treatment for UTIs in the Illawarra and South Coast

Women in the Illawarra and South Coast regions will soon have easier access to treatment for uncomplicated urinary tract infections (UTIs) following the successful completion of a 12-month pharmacy trial in NSW. 


Starting from 1 June, pharmacists across NSW who have undergone the necessary training will be able to provide consultations and prescriptions for UTIs.



The trial, which included over one thousand pharmacies throughout the state, has facilitated more than 18,000 consultations in the past year alone. The trial also included dispensation of the oral contractive pill. Kiama participated with four pharmacies, allowing for 67 UTI consultations and two involving the contraceptive pill. 


The NSW Government’s $6 million investment in the trial enabled more than 16,000 women access to UTI treatment from their local community pharmacists, providing quick and convenient health care and easing existing pressure on general practices. 


The Minister for Health, Ryan Park, says, “The NSW Government is committed to taking pressure off GPs and primary care services and we are constantly evaluating ways we can deliver healthcare more efficiently as well as safely.” 



The trial provided compensation to participating pharmacies, with the NSW Government contributing $20 per patient keeping costs low. However consumers should note that pharmacies may set their own fees for the services, in addition to medication costs.  


For convenience, pharmacies offering the UTI service will be listed on the National Health Directory Service. Eligible women, aged between 18 and 65 who display symptoms of an uncomplicated UTI will be eligible to receive treatment at participating pharmacies. 



A comprehensive evaluation of the trial is underway which will focus on aspects such as patient satisfaction, antibiotic supply rates, referral frequencies and any additional medical or pharmacy services that may be required post-consultation. 


The successful completion of the trial underscores the government’s efforts to improve access to medication, enhance patient care, and alleviate pressure on healthcare services.